Department of Endocrinology and Metabolism, Zhongshan Hospital and Fudan Institute for Metabolic Diseases, Fudan University, 180 Fenglin Rd, Shanghai, 200032, China.
Department of Integrated Medicine, Guangxi Medical University Cancer Hospital, Nanning, China.
Lipids Health Dis. 2024 Apr 2;23(1):95. doi: 10.1186/s12944-024-02092-2.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease that affects over 30% of the world's population. For decades, the heterogeneity of non-alcoholic fatty liver disease (NAFLD) has impeded our understanding of the disease mechanism and the development of effective medications. However, a recent change in the nomenclature from NAFLD to MASLD emphasizes the critical role of systemic metabolic dysfunction in the pathophysiology of this disease and therefore promotes the progress in the pharmaceutical treatment of MASLD. In this review, we focus on the mechanism underlying the abnormality of hepatic lipid metabolism in patients with MASLD, and summarize the latest progress in the therapeutic medications of MASLD that target metabolic disorders.
代谢相关脂肪性肝病（MASLD）是导致慢性肝病的主要原因，影响着全球超过 30%的人口。几十年来，非酒精性脂肪性肝病（NAFLD）的异质性阻碍了我们对疾病机制的理解和有效药物的开发。然而，最近将其命名从 NAFLD 改为 MASLD，强调了全身性代谢功能障碍在该疾病病理生理学中的关键作用，从而推动了 MASLD 药物治疗的进展。在这篇综述中，我们重点关注 MASLD 患者肝内脂质代谢异常的机制，并总结了针对代谢紊乱的 MASLD 治疗药物的最新进展。
